Radium-223 (Ra-223), a bone-targeted alpha therapy, is a well-tolerated treatment option that prolongs survival in men with mCRPC to bone. Docetaxel targets microtubule trafficking improving survival in the mCRPC and metastatic hormone-sensitive settings.